US FDA Clears IND for 4DMT’s Wet AMD Gene Therapy Candidate

4D Molecular Therapeutics announced Oct. 6 that the US FDA had cleared the investigational new drug application (IND) for 4D-150 for wet age-related macular degeneration (wet AMD). 4D-150 is a dual-transgene intravitreal gene therapy that targets four distinct angiogenic factors, which 4DMT says has the potential for broad and durable efficacy after a single intravitreal administration in patients with wet …

Adverum Presents Data Showing Gene Therapy Maintained Efficacy, Durability, Safety in Wet AMD Patients

Adverum Biotechnologies announced new long-term data from the OPTIC clinical trial of ADVM-022 single, in-office intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). Safety and efficacy data from patients followed through 2 years post injection are being presented at the Retina Society’s 54th Annual Scientific Meeting in Chicago. The presentation is available on …

BVI Announces Investment and Collaboration with Beyeonics Vision

BVI announced an investment in augmented reality company Beyeonics Vision, a medical technology subsidiary of Elbit Systems Ltd.Terms of the deal were not disclosed.Beyeonics Vision uses integrated augmented reality, tracking, and image processing/AI platforms to deliver improved visualization, optimized workflow, and real-time support to surgeon decision-making process in the operating room, according to a company news release. The collaboration is …

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

Eyevensys has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology.  Terms of the deal were not diclosed. Eyevensys has developed a non-viral gene therapy ocular drug delivery platform with a proprietary Electrotransfection System designed to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle and sustainably treat major eye diseases. …

Novartis Acquires Arctos Medical, Expanding Optogenetic Gene Therapy Pipeline

Swiss company Novartis announced Sept. 21 that it had acquired Arctos Medical, developer of a potential optogenetic AAV gene therapy for inherited retinal disease. Financial details were not disclosed. The move comes a year after Novartis paid $150 million up front and a potential $130 million in milestone payments in September 2020 for Vedere Bio of Cambridge, Massachusetts.

Diagnostic Device Makers Luneau, Optovue Announce Merger

Ophthalmic diagnostic device manufacturers Luneau Technology, of France, and Optovue, of Fremont, California, have announced an agreement to merge. Terms of the deal were not disclosed. The companies said their combined power will allow them to leverage their industry expertise, strengthen their international footprint, and provide customers with a full product range.

Stuart Therapeutics Completes Enrollment in Phase II Trial for Dry Eye Candidate

Stuart Therapeutics, of Stuart, Florida, announced Sept. 8 that it had completed enrollment of 150 patients in a Phase II clinical trial of its eye drop candidate ST-100 in dry eye disease. The multi-center, randomized, double-masked study will evaluate two different dose levels vs. placebo.  The company, founded in 2017, has exclusively licensed the worldwide rights to a family of …

Novel digital therapy for amblyopia demonstrates positive phase 3 results

Luminopia One, an investigational digital therapy that allows patients with amblyopia to watch visually modified TV shows and movies to improve vision, has shown positive results, according to a press release from Luminopia. The phase 3 multicenter, randomized, controlled pivotal clinical trial, published in Ophthalmology, was designed to test the safety and efficacy of Luminopia One in patients with amblyopia aged …